CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Paladin Labs Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Paladin Labs Inc.
100 Alexis-Nihon Blvd Suite 600
Phone: (514) 340-1112p:514 340-1112 SAINT-LAURENT, QC  H4M 2P2  Canada Ticker: PLBPLB
Filed for Bankruptcy on 8/16/2022
This company was Merged or Acquired on 2/28/2014.
Case #22-22617, filed in the U.S. Bankruptcy Court for the Southern District of New York (White Plains)
This case is being Jointly Administered under the lead case filed for Endo International plc Case #22-22549.
On 8/17/2022, Paladin Labs Canadian Holding Inc. and Paladin Labs Inc. filed for recognition of their Chapter 11 proceedings under Part IV of the Creditors Companies Arrangement Act (CCAA) with the Ontario Superior Court of Justice, Commercial List. On 8/19/2022, the Court granted its recognition and protection for the Companies' United States proceedings.
This is a Subsidiary, click here for the Parent Company
Business Summary
Paladin Labs Inc. is a specialty pharmaceutical company focused on developing, acquiring, in-licensing, marketing and distributing pharmaceutical products. The Company’s product portfolio includes Tridural, Abstral and Trelstar. Tridural is a once-a-day tramadol product indicated as a first-line therapy for adults with moderate pain requiring several days or more of treatment. Abstral is a sublingual tablet used for the management of breakthrough cancer pain in patients who are already tolerant to other opioid analgesics. Trelstar is an injectable, luteinizing hormone releasing hormone agonist indicated for the palliative treatment of prostate cancer and endometriosis. In July 2013, the Company became the sole holder of Allon Therapeutics Inc. Effective January 1, 2014, Paladin Labs Inc. acquired Triton Pharma Inc.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201312/31/2012Yes-Yes--

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Jonathan R.Goodman 53 5/29/2012 1/1/1995
Interim President, Interim Chief Executive Officer, Secretary, Director Mark A.Beaudet 8/18/2011 1/1/1996
Chief Financial Officer SamiraSakhia 52 7/16/2001 7/16/2001
7 additional Officers and Directors records available in full report.

Business Names
Business Name
Allon Therapeutics Inc.
Ativa Pharma S.A.
BioEnvelop Inc.
6 additional Business Names available in full report.

General Information
Number of Employees: 403 (As of 12/31/2012)
Outstanding Shares: 20,765,385 (As of 2/5/2014)
Shareholders: 1,292
Stock Exchange: TSE
Federal Tax Id: 981181410
Fax Number: (514) 340-1112


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, August 28, 2023